2002 - 2003 Molecular mechanism and possible therapeutic target of BAFF upregulation in SLE
2000 - 2003 Analysis of the aberrant TCRζ mRNA 3'UTR in SLE patient T cells
1999 - 2000 全身性エリテマトーデス患者T細胞に発現されるTCRζ鎖の異常に関する研究
1997 - 1998 Role of alphaEbeta7 on tissue destruction of autoimmune diseases
1997 - 1998 リボゾーム蛋白S1による抗DNA抗体産生の機序に関する研究
1997 - SLE患者末梢血T細胞におけるTCRζ鎖発現低下の分子生物学的機序
1996 - Down-regulation of TCRζ in the peripheral blood from systemic lupus erythematosus patients
Show all
Papers (161):
Kensei Tsuzaka, Yoko Akiyama, Masayoshi Nagata. Efficacy of Infliximab, Adalimumab, and Tocilizumab Can be Improved Under the Baseline ADAMTS5 Selection. ARTHRITIS & RHEUMATOLOGY. 2014. 66. S1106-S1106
Kensei Tsuzaka, Masako Takao, Jiro Nishida. ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM. 2013. 65. S962-S963
Tsuzaka K, Takao M, Nishida J. Plasma short-talin is a new rheumatoid arthritis monitoring biomarker independent of the inflammatory markers. Arthritis Rheum. 2013. 65. S1024
Kensei Tsuzaka, Masako Takao, Naoshi Shinozaki, Jiro Nishida. Talin Is Cleaved and Expressed As a Short Form in Patients with Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM. 2012. 64. 10. S505-S505
K. Tsuzaka, M. Nagata, K. Amano, T. Mimura, S. Kagami, Y. Miwa, K. Ikeda, T. Mitsuka, H. Kanai, I. Sekigawa. VALIDATION OF THE BASELINE ADAMTS5 MRNA LEVELS AS A PREDICTION BIOMARKER FOR THE EFFICACY OF INFLIXIMAB; A MULTICENTER CLINICAL TRIAL. ANNALS OF THE RHEUMATIC DISEASES. 2016. 75. 198-198
K. Tsuzaka, S. Nogawa, J. Nishida. ADAMTS5, WHICH HAS NEGATIVE CORRELATION WITH IL-6, IS A BIOMARKER FOR THE EFFICACY PREDICTION OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES. 2014. 73. 384-384